The World Health Organization recommends dolutegravir (DTG) as the for first-line and second-line antiretroviral therapy (ART) worldwide. However, little is known about the acceptability and tolerability...
The Makerere-Yale-University of California Berkeley PART Program (& Makerere HIV ImS Training Program), sponsored by the National Institutes of Health Fogarty International Center D43 HIV/AIDS Research...
